skip to Main Content
  1. A unique theranostic isotope and targeting molecule to treat equine laminitis“, CA Doerr et al., poster presentation at the Society of Nuclear Medicine and Molecular Imaging, July 13-16, 2020, virtual meeting
  2. “Radiation safety considerations in the treatment of canine skeletal conditions using 153Sm, 90Y and 117mSn“, RE Wendt et al., Health Phys. 118(6):702-710;2020
  3. Harnessing Sn-117m for improved quality of life“, NR Stevenson, oral presentation at 10ICI, February 3-7, 2020, Kuala Lampur, Malaysia
  4. Electron therapy hormesis in inflammatory vascular disease“, GR Gonzales et al., oral presentation at 10 ICI, February 3-7, 2020, Kuala Lampur, Malaysia
  5. Production of Sn-117m in the BR2 high-flux reactor“, B Ponsard, oral presentation at 10 ICI, February 3-7, 2020, Kuala Lampur, Malaysia
  6. Localizing apoptosis-inducing Sn-117m to brain neuroinflammatory cells“, GR Gonzales et al., oral presentation at 10 ICI, February 3-7, 2020, Kuala Lampur, Malaysia
  7. A new radioisotope-based treatment for veterinary and human arthritis“, GR Gonzales et al., oral presentation at 10ICI, February 3-7, 2020, Kuala Lampur, Malaysia
  8. “A novel Sn-117m colloid for human radiosynoviorthesis clinical trials”, NR Stevenson et al., oral presentation at The 32nd Annual Congress of the European Association of Nuclear Medicine, October 11-16, 2019, Barcelona, Spain
  9. “Radiosynoviorthesis using Sn-117m colloid to treat canine elbow osteoarthritis demonstrates efficacy and safety”, CA Doerr et al., poster presentation at The 32nd Annual Congress of the European Association of Nuclear Medicine, October 11-16, 2019, Barcelona, Spain
  10. A reinjection study of Sn-117m colloid to treat canine osteoarthritis shows safety and efficacy”, CA Doerr et al., oral presentation at The 32nd Annual Congress of the European Association of Nuclear Medicine, October 11-16, 2019, Barcelona, Spain
  11. “Intraarticular injection of a tin-117m radiosynoviorthesis agent in normal canine elbows causes no adverse effects“, JC Lattimer et al., Veterinary Radiol Ultrasound. 2019; Sep;60(5):567-574, Epub 2019 Jun 2
  12. Production of Sn-117m in the BR2 high-flux reactor“, B Ponsard et al., poster presentation at the 2019 Theranostics World Congress, March 1-3, 2019, Jeju, Korea
  13. “Sn-117m homogeneous colloid: A new therapeutic agent in Canada”, CA Doerr et al., Sunrise Symposium oral presentation at The Canadian Association of Nuclear Medicine 2019 Annual Meeting, February 7-10, 2019, Quebec City, Canada
  14. Misadministration of Sn-117m colloid during radiosynoviorthesis presents no safety concerns“, CA Doerr et al., oral presentation at The Canadian Association of Nuclear Medicine Annual Meeting, February 7-10, 2019, Quebec City, Canada
  15. Long term therapy for chronic osteoarthritis associated with elbow dysplasia“, JM Donecker, oral presentation at Association of Veterinary Orthopedics and Research Annual Meeting, January 24-26, 2019, San Diego CA
  16. “Canine Sn-117m colloid intra-articular injection release guidance”, JM Donecker et al., oral presented to the American College of Veterinary Radiology Annual Meeting, October 14-19, 2018, Fort Worth, TX
  17. “A novel molecule for the systemic imaging and treatment of rheumatoid arthritis”, NR Stevenson et al., e-poster presentation at the European Association of Nuclear Medicine 2018 Annual Meeting, October 12-16, 2018, Dusseldorf, Germany
  18. “Applications of Sn-117m and the potential world supply and demand”, NR Stevenson, oral presentation at KARA Radiation Promotion Conference, Sept 14, 2018, Busan, Korea
  19. Monte Carlo simulation of the dose from radiosynoviorthesis using Sn-117m, Er-169, and Re-186 including stochastic macrophage motion“, AC Gupta et al., oral presentation at the American Association of Physicists in Medicine 2018 Annual Meeting, July 29-August 2, 2018, Nashville, TN
  20. Synovetin OA results of clinical trials using a homogeneous tin colloid for treatment of elbow osteoarthritis“, JM Donecker, oral presentation at the Association for Veterinary Orthopedic Research and Education Annual Meeting, July 19-21, 2018, Ketchum, ID
  21. Release of dogs following Sn-117m colloid intra-articular injections”, RE Wendt et al., oral presentation at the Society of Nuclear Medicine and Molecular Imaging 2018 Annual Meeting, June 23-27, 2018, Philadelphia, PA
  22. A Monte Carlo study of Sn-117m radiosynoviorthesis to treat arthritic joints”, AC Gupta et al., oral presentation at the Society of Nuclear Medicine and Molecular Imaging 2018 Annual Meeting, June 23-27, 2018, Philadelphia, PA
  23. Sn-117m –A new isotope for treating arthritis“, NR Stevenson, oral presentation at the International Isotope Society Symposium 2018 Meeting, June 3-7, 2018, Prague, Czech Republic
  24. Advances in the global use of isotopes for medicine, industry and environmental science”, NR Stevenson, invited lecture at the American Physical Society Q2C Meeting, April 14-17, 2018, Columbus, OH
  25. Experience using homogeneous Sn-117m colloid for RSO”, CA Doerr, invited lecture at the Canadian Association of Nuclear Medicine 2018 Annual Meeting, March 22-25, 2018, Vancouver BC, Canada
  26. “Manufacturing and applications of Sn-117m in nuclear medicine”, NR Stevenson, invited lecture at the American Chemical Society Spring 2018 National Meeting, March 18-22, 2018, New Orleans, LA
  27. “ Tin-117m: A new isotope and approach to radiosynoviorthesis and other therapies“, NR Stevenson, invited lecture, 39th High Country Nuclear Medicine Conference, March 3-7, 2018, Sun Valley, ID
  28. Radiosynoviorthesis: a new therapeutic and diagnostic tool for canine joint inflammation. JM Donecker, NR Stevenson. In: Fox SM, ed. Multimodal Management of Canine Osteoarthritis (2nd Edition). CRC Press, 2017:75-80
  29. Simulation of Sn-117m radiosynoviorthesis including phagocytotic migration within the joint“, RE Wendt et al., abstract presentation at the 9th International Conference on Isotopes, November 12-16, 2017, Doha, Qatar
  30. Nuclear medicine applications of the novel theranostic isotope Sn-117m“, GR Gonzales et al., abstract presentation at the 9th International Conference on Isotopes, November 12-16, 2017, Doha, Qatar
  31. Retention and radiation field of a Sn-117m colloidal syspension in canine intra-articular injections“, NR Stevenson et al., abstract presentation at the 9th International Conference on Isotopes, November 12-16, 2017, Doha, Qatar
  32. Radiosynoviorthesis: Radioisotope therapy for arthritic conditions“, K Liepe et al., abstract presentation at the 9th International Conference on Isotopes, November 12-16, 2017, Doha, Qatar
  33. Novel treatments for arthritis in humans and animals using Sn-117m colloids and labeled molecules“, NR Stevenson, abstract presentation at the 9th International Conference on Isotopes, November 12-16, 2017, Doha, Qatar
  34. Production and preparation of Sn-117m from the BR2 reactor“, B Ponsard et al., 9th International Conference on Isotopes, November 12-16, 2017, Doha, Qatar
  35. Preclinical trials using Sn-117m homogeneous colloid in radiosynoviorthesis“, CA Doerr, invited oral presentation at the 12th International Conference on Radiopharmaceutical Therapy, October 19, 2017, Vienna, Austria
  36. Manufacturing and characteristics of Sn-117m based radiopharmaceuticals and medical devices“, NR Stevenson, invited oral presentation at the 12th International Conference on Radiopharmaceutical Therapy, October 19, 2017, Vienna, Austria
  37. Nuclear medicine applications of Sn-117m“, GR Gonzales, invited oral presentation at the 12th International Conference on Radiopharmaceutical Therapy, October 19, 2017, Vienna, Austria
  38. Oral presentations in CE98: Targeting radionuclide therapy in various non-malignant conditions using radiosynoviorthesis (RSO),  “Global experience with radioisotopes used for RSO”, K Liepe,  “Characteristics and comparison of RSO isotopes including Sn-117m“, NR Stevenson, “U.S. Experience using New Isotope Sn-117m Homogeneous Colloid for RSO in Canines with OA“, JC Lattimer, and “Canadian Clinical Trial Experience using Re-186 and Y-90 in RSO of Human Arthritides,” P Cohen, at the Society of Nuclear Medicine and Molecular Imaging 2017 Annual Meeting, June 14, 2017, Denver, CO
  39. A comparison of tissue doses from colloidal Sn-117m, Re-186, Y-90 and Er-169 for radiosynoviorthesis using Monte Carlo simulation”, RE Wendt et al., oral presentation at the Society of Nuclear Medicine and Molecular Imaging 2017 Meeting, June 13, Denver, CO
  40. External radiation exposure following Sn-117m colloid intra-articular injections“, RE Wendt et al., poster presentation at the Society of Nuclear Medicine and Molecular Imaging 2017 Meeting, June 13, Denver, CO
  41. Preclinical evaluation of Sn-117m colloid as a radiosynoviorthesis agent for treatment of canine elbow joint osteoarthrosis“, JC Lattimer et al., oral presentation at the Veterinary Orthopedic Society 2017 Annual Meeting, March 13, 2017, Snowbird, UT
  42. My biz on isotopes: Serene, LLC“, CA Doerr, World Council on Isotopes February 2017 e-Newsletter, pp 8-11
  43. “RSO study update and preclinical evaluation of Sn-117m colloid as a radiosynoviorthesis agent for treatment of canine elbow joint osteoarthrosis“, JM Donecker et al., oral presentation at the Association of Veterinary Orthopedic Research and Education meeting, January 27, 2017, San Diego, CA
  44. “Improving radiosynoviorthesis using a Sn-117m colloid“, K Liepe et al., oral presentation at the International Conference on Radiopharmaceutical Therapy 2016 Annual Meeting, November 13-17, Kerala, India
  45. A Sn-117m electroplated cholangiocarcinoma Stent“, GR Gonzales et al., poster presentation at the International Conference on Radiopharmaceutical Therapy 2016 Annual Meeting, November 13-17, Kerala, India
  46. “Sn-117m colloid radiosynoviorthesis effects on canine OA synovitis as evaluated by PET, MRI, and behavioral measures“, CA Doerr et al., oral presentation at the International Conference on Radiopharmaceutical Therapy 2016 Annual Meeting, November 13-17, Kerala, India
  47. Production and characteristics of a novel Sn-117m particulate suspension for application in human and veterinary radiosynoviorthesis“, NR Stevenson et al., oral presentation at the International Conference on Radiopharmaceuthical Therapy 2016 Annual Meeting, November 13-17, Kerala, India
  48. Preclinical evaluation of tin-117m colloid as a radiosynoviorthesis agent for the treatment of canine elbow joint osteoarthrosis“, JC Lattimer, et al., oral presentation at the American College of Veterinary Radiology, October 19-22, 2016, Orlando, FL
  49. 117mSn colloid as a potential candidate to replace 169Er colloids in radiosynovectomy of small joints“, K Liepe, et al., oral presentation at the European Association of Nuclear Medicine 2016 Annual Meeting, October 15-19, 2016, Barcelona, Spain
  50. Sn-117m colloid distribution and autoradiography in the normal canine elbow“, GR Gonzales, et al., oral presentation at the European Association of Nuclear Medicine 2016 Annual Meeting, October 15-19, 2016, Barcelona, Spain
  51. Human brain dosimetry in disrupted blood brain barrier using [Sn-117m]-DOTA-Annexin V (SnDAV): A model for targeting aged microglia in Alzheimer’s disease“, GR Gonzales, et al., poster presentation at Alzheimer’s Association International Conference, July 24-28, 2016, Toronto, Canada
  52. “Canine joint therapy with syovetin OA™ has early disease-modifying effects by breaking the inflammatory cycle associated with synovitis”, technical bulletin produced by Serene, LLC, June 20, 2016
  53. A comparison of Er-169 and Sn-117m radiation synoviorthesis using Monte Carlo simulation“, RE Wendt, et al., oral presentation at the Society of Nuclear Medicine and Molecular Imaging 2016 Meeting, June 14, San Diego, CA
  54. “Retention and biodistribution of Sn-117m colloid in intra-articular injections”, JC Lattimer, et al., oral presentation at the Society of Nuclear Medicine and Molecular Imaging 2016 Meeting, June 14, San Diego, CA
  55. Validation of the use of homogeneous Sn-117m colloid radiosynoviorthesis in a GLP osteoarthritis rat model“, CA Doerr, et al., oral presentation at the Society of Nuclear Medicine and Molecular Imaging 2016 Meeting, June 14, San Diego, CA
  56. Non-invasive therapy of symptomatic high grade carotid stenosis using [Sn-117m]-DOTA-annexin V“, GR Gonzales, et al., oral presentation, American Association of Neurology 2016 Meeting, April 16, 2016, Vancouver, BC
  57. Radiosynoviorthesis: A new therapeutic and diagnostic tool for canine joint inflammation“, NR Stevenson, et al., World Council on Isotopes e-Newsletter, 2016 March, Vol. 5, Issue 3
  58. Manufacturing and nuclear medicine applications of the novel isotope Sn-117m“, NR Stevenson et al., invited oral presentation at the International Conference on Translational Research in Radio-Oncology | Physics for Health in Europe, February 15-19, 2016, Geneva, Switzerland
  59. Radiosynoviorthesis: A new therapeutic and diagnostic tool for canine joint inflammation“, technical bulletin produced by Serene, LLC, January 20, 2016
  60. Novel treatments for arthritis in humans and animals using the theranostic isotope Sn-117m:  Colloids and labeled molecules“, NR Stevenson et al., platform presentation at the International Chemical Congress of Pacific Basin Societies, December 17, 2015, Honolulu, HI
  61. Evaluation of homogeneous Sn-117m colloid radiosynovectomy in normal dogs using scintigraphy, PET-MRI and other modalities“, JC Lattimer, et al., poster presentation at the World Molecular Imaging Congress, September 3, 2015, Honolulu HI
  62. Methods of producing high specific activity Sn-117m with commercial cyclotrons“, NR Stevenson, et al., Journal of Radioanalytical and Nuclear Chemistry, 305, 99-108(2015)
  63. “Homogeneous Sn-117m colloid radiosynovectomy results in rat models of joint disease”, CA Doerr, et al.Poster abstract presentation at the Society of Nuclear Medicine and Molecular Imaging, June 6-10, 2015, Baltimore, MD
  64. Homogeneous Sn-117m colloid – A novel radiosynovectomy agent”, S6;03, NR Stevenson, et al., oral presentation at the 11th International Conference on Radiopharmaceutical Therapy, May 4-8, 2015, Innsbruck, Austria
  65. A novel Sn-117m colloid for radiosynovectomy”, SC Srivastava, et al., oral presentation at the Society of Nuclear Medicine and Molecular Imaging, January 22-25, 2015, San Antonio, TX
  66. Enabling simultaneous imaging and treatment with the theragnostic radionuclide Tin-117m”, SC Srivastava, TERACHEM, September 10-13, 2014, Italy
  67. Methods of producing high specific activity Sn-117m with commercial cyclotrons”, NR Stevenson, 8th International Conference on Isotopes, August 2014, Chicago, IL
  68. “Therapeutic radionuclides: Production, physical characteristics, and applications” in RP Baum (Ed.), Therapeutic Nuclear Medicine, Springer, SC Srivastava and LF Mausner, (2014), pp 12-46
  69. Preparation and evaluation of Sn-117m annexin for vulnerable plaque”, J Simon, et al., August, at NUCL-10, the 8th International Conference on Isotopes, August 24-29, 2014, Chicago, IL
  70. Production of commercial specific high activity Sn-117m radiochemical and chelates,” NR Stevenson, DOE-NP SBIR/STTR Exchange Meeting, August 24-28, 2014
  71. Sn117m-DOTA-Annexin as a novel vulnerable plaque tracer. First time in humans trial”, R Jaimovich , et al., IAEA International Conference on Integrated Medical Imaging in Cardiovascular Disease, September 30-October 4, 2013, Vienna, Austria
  72. Manufacturing and integrated medical imaging of high specific activity [Sn-117m]-annexin in cardiovascular disease”, NR Stevenson, et al., IAEA International Conference on Integrated Medical Imaging in Cardiovascular Disease, September 30-October 4, 2013, Vienna, Austria
  73. Simultaneous imaging and treatment of vulnerable plaques with tin-117m-DOTA-Annexin”, SC Srivastava, et al., presentation at the International Workshop on Innovative Personalized Radioimmunotherapy: Latest Progress in the Field of RadioImmunoTherapy, July 9-12, 2013, Nantes, France
  74. “Production and applications of high specific activity Sn-117m-DOTA-Annexin”, SC Srivastava, et al., presentation at the International Workshop on Innovative Personalized Radioimmunotherapy: Latest Progress in the Field of RadioImmunoTherapy, July 9-12, 2013, Nantes, France,
  75. “Production and applications of high specific activity Sn-117m labeled compounds”, NR Stevenson, presentation at the Radiometals 2013 Conference, June 13-16, 2013, Sonoma Valley, CA
  76. Targeting of vulnerable plaque using [tin-117m]-DOTA-annexin”, HW Strauss, et al., Society of Nuclear Medicine and Molecular Imaging, June 8-12, 2013, Vancouver, BC, Canada
  77. Theragnostic potential of Sn-117m for the molecular targeting and therapy of vulnerable plaque”, SC Srivastava, et al., Society of Nuclear Medicine and Molecular Imaging, June 8-12, 2013, Vancouver, BC, Canada,
  78. Production and applications of very high specific activity Sn-117m and labeled chelates/molecules”, NR Stevenson, et al., ISRS, May 12-17, 2013, Juju, Korea
  79. “Sn-117m labeled annexin for vulnerable plaque”, J Simon, et al., American Chemical Society, April 2013, New Orleans, LA
  80. Production and applications of very high specific activity Sn-117m”, NR Stevenson, et al., American Chemical Society, April 7-11, 2013, New Orleans, LA
  81. Paving the way to personalized medicine for treatment of cancer and other inflammatory disorders”, S-33 SC Srivastava, presentation at the International Conference on Radiopharmaceutical Therapy, November 25-29, 2012, Levi, Finland
  82. Tin-117m-DOTA-annexin for imaging and treating vulnerable plaque”, S-61, GR Gonzales, presentation at the International Conference on Radiopharmaceutical Therapy, November 25-29, 2012, Levi, Finland
  83. Paving the way to personalized medicine: Production of some promising theragnostic radionuclides at Brookhaven National Laboratory”, SC Srivastava, Semin. Nucl. Med. 2012 May;42(3):151-163
  84. Simultaneous localization and treatment of vulnerable plaque by tin-117m conversion electrons: First-in-human results”, R Virmani, Transcatheter Cardiovascular Therapeutics 2012 Innovations session: October 22-26, 2012, Miami, FL
  85. “Production of commercial high specific activity Sn-117m radiochemical and chelates”, NR Stevenson et al., SBIR Phase I Grant Period of Performance 1-12, 2012
  86. “Theragnostic radiopharmaceuticals: An emerging paradigm empowering personalised medicine”, O-0129, SC Srivastava, International Conference on Radiopharmaceutical Therapy, world J Nucl Med 2011 Jul-Dec; 10(2):142-177
  87. 25 years of continuous operation of the Seattle cyclotron facility,” R Risler et al., Proceedings of CYCLOTRONS, Sept 10, 2010, Lanzhou, China
  88. Production of Sn-117m in the BR2 high-flux reactor“, B Ponsard, et al., Applied Radiation and Isotopes, 67 (2009) 1158-1161
Back To Top